We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...
Bidding to buy metabolic medicines biotech Metsera in September came down to two pharmaceutical giants, with Novo Nordisk’s higher offer losing out to Pfizer’s $4.9 billion price in part due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results